Progress in Neurotherapeutics and Neuropsychopharmacology.
General Material Designation
[Book]
First Statement of Responsibility
edited by Jeffrey L. Cummings.
Volume Designation
Volume 1.dollar52006. /
.PUBLICATION, DISTRIBUTION, ETC
Place of Publication, Distribution, etc.
Cambridge :
Name of Publisher, Distributor, etc.
Cambridge University Press,
Date of Publication, Distribution, etc.
2006.
PHYSICAL DESCRIPTION
Specific Material Designation and Extent of Item
1 online resource (184 pages)
MATERIAL SPECIFIC AREA: ELECTRONIC RESOURCE CHARACTERISTICS
Designation and extent of file
Electronic book.
GENERAL NOTES
Text of Note
Title from publishers bibliographic system (viewed on 22 Dec 2011).
SUMMARY OR ABSTRACT
Text of Note
Published annually, volumes in this series provide readers with updates of clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists. This volume was first published in 2006.